中国学者近期发表的论文
1.	Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma. Author: Ma H1,2, Yang W1,2, Zhang L1,2, Liu S1,2, Zhao M3, Zhou G3, Wang L4, Jin S5,6, Zhang Z7,8, Hu J9,10. Journal: Br J Cancer. 2019 Feb;120(3):317-330. doi: 10.1038/s41416-018-0352-y. Epub 2018 Dec 17.    PubMed      DOI
2.	(Pro)renin receptor promotes colorectal cancer through the Wnt/beta-catenin signalling pathway despite constitutive pathway component mutations. Author: Wang J1,2,3, Shibayama Y2, Zhang A2, Ohsaki H4, Asano E, Suzuki Y5, Kushida Y6, Kobara H7, Masaki T7, Wang Z3, Nishiyama A8. Journal: Br J Cancer. 2019 Jan;120(2):229-237. doi: 10.1038/s41416-018-0350-0. Epub 2018 Dec 17.    PubMed      DOI
3.	Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy. Author: Liu C1, He H1,2, Li X1,3, Su MA4, Cao Y5,6. Journal: Br J Cancer. 2019 Feb;120(3):346-355. doi: 10.1038/s41416-018-0363-8. Epub 2018 Dec 27.    PubMed      DOI
4.	A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. Author: Fujiwara Y1, Mukai H2, Saeki T3, Ro J4, Lin YC5, Nagai SE6, Lee KS7, Watanabe J8, Ohtani S9, Kim SB10, Kuroi K11, Tsugawa K12, Tokuda Y13, Iwata H14, Park YH15, Yang Y16,17, Nambu Y18. Journal: Br J Cancer. 2019 Mar;120(5):475-480. doi: 10.1038/s41416-019-0391-z. Epub 2019 Feb 12.    PubMed      DOI
5.	Genome-wide association study of germline variants and breast cancer-specific mortality. Author: Escala-Garcia M1, Guo Q2, Dörk T3, Canisius S1,4, Keeman R1, Dennis J5, Beesley J6, Lecarpentier J5, Bolla MK5, Wang Q5, Abraham J7,8,9, Andrulis IL10,11, Anton-Culver H12, Arndt V13, Auer PL14,15, Beckmann MW16, Behrens S17, Benitez J18,19, Bermisheva M20, Bernstein L21, Blomqvist C22,23, Boeckx B24,25, Bojesen SE26,27,28, Bonanni B29, Børresen-Dale AL30,31,32,33,34,35,36,37,38,39, Brauch H40,41,42, Brenner H13,42,43, Brentnall A44, Brinton L45, Broberg P46, Brock IW47, Brucker SY48, Burwinkel B49,50, Caldas C8,9,51, Caldés T52, Campa D17,53, Canzian F50, Carracedo A54,55,56, Carter BD57, Castelao JE58, Chang-Claude J17,59, Chanock SJ45, Chenevix-Trench G6, Cheng TD60, Chin SF61, Clarke CL62; NBCS Collaborators, Cordina-Duverger E63, Couch FJ64, Cox DG65,66, Cox A47, Cross SS67, Czene K68, Daly MB69, Devilee P70,71, Dunn JA72, Dunning AM7, Durcan L73,74, Dwek M75, Earl HM9,76, Ekici AB77, Eliassen AH78,79, Ellberg C46, Engel C80,81, Eriksson M68, Evans DG82,83, Figueroa J45,84,85, Flesch-Janys D86,87, Flyger H88, Gabrielson M68, Gago-Dominguez M54,89, Galle E24,25, Gapstur SM57, García-Closas M45,90, García-Sáenz JA52, Gaudet MM57, George A91,92, Georgoulias V93, Giles GG94,95,96, Glendon G10, Goldgar DE97, González-Neira A18, Alnæs GIG30, Grip M98, Guénel P63, Haeberle L99, Hahnen E100,101, Haiman CA102, Håkansson N103, Hall P68,104, Hamann U105, Hankinson S106, Harkness EF107,108,109, Harrington PA7, Hart SN110, Hartikainen JM111,112,113, Hein A16, Hillemanns P3, Hiller L72, Holleczek B114, Hollestelle A115, Hooning MJ115, Hoover RN45, Hopper JL95, Howell A116, Huang G105, Humphreys K68, Hunter DJ79,117,118, Janni W85, John EM119,120,121, Jones ME90, Jukkola-Vuorinen A122, Jung A17, Kaaks R17, Kabisch M105, Kaczmarek K123, Kerin MJ124, Khan S125, Khusnutdinova E20,126, Kiiski JI125, Kitahara CM127, Knight JA128,129, Ko YD130, Koppert LB131, Kosma VM111,112,113, Kraft P79,117, Kristensen VN30,31,32,33,34,35,36,37,38,39, Krüger U46, Kühl T59, Lambrechts D24,25, Le Marchand L132, Lee E102, Lejbkowicz F133, Li L134, Lindblom A135, Lindström S136,137, Linet M127, Lissowska J138, Lo WY40,41, Loibl S139, Lubiński J123, Lux MP99, MacInnis RJ94,95, Maierthaler M50, Maishman T73,74, Makalic E95, Mannermaa A111,112,113, Manoochehri M105, Manoukian S140, Margolin S141, Martinez ME89,142, Mavroudis D93, McLean C143, Meindl A144, Middha P17,145, Miller N124, Milne RL94,95, Moreno F52, Mulligan AM146,147, Mulot C148, Nassir R149, Neuhausen SL21, Newman WT82,83, Nielsen SF26,27, Nordestgaard BG26,27,28, Norman A110, Olsson H46, Orr N150, Pankratz VS151, Park-Simon TW3, Perez JIA152, Pérez-Barrios C153, Peterlongo P154, Petridis C155, Pinchev M133, Prajzendanc K123, Prentice R14, Presneau N75, Prokofieva D126, Pylkäs K156,157, Rack B144, Radice P158, Ramachandran D3, Rennert G133, Rennert HS133, Rhenius V7, Romero A153, Roylance R159, Saloustros E160, Sawyer EJ155, Schmidt DF95, Schmutzler RK100,101, Schneeweiss A49,161, Schoemaker MJ91, Schumacher F162, Schwentner L85, Scott RJ163,164,165,166, Scott C110, Seynaeve C115, Shah M7, Simard J167, Smeets A168, Sohn C161, Southey MC169,170, Swerdlow AJ91,171, Talhouk A172,173,174, Tamimi RM78,79,117, Tapper WJ175, Teixeira MR176,177, Tengström M111,178,179, Terry MB180, Thöne K59, Tollenaar RAEM181, Tomlinson I182,183, Torres D105,184, Truong T63, Turman C79, Turnbull C91, Ulmer HU185, Untch M186, Vachon C110, van Asperen CJ187, van den Ouweland AMW188, van Veen EM82,83, Wendt C189, Whittemore AS120,121, Willett W79,190,191, Winqvist R156,157, Wolk A192, Yang XR45, Zhang Y13,42, Easton DF5,7, Fasching PA16,193, Nevanlinna H125, Eccles DM74, Pharoah PDP5,7, Schmidt MK1,194. Journal: Br J Cancer. 2019 Mar;120(6):647-657. doi: 10.1038/s41416-019-0393-x. Epub 2019 Feb 21.    PubMed      DOI
6.	Ezrin promotes breast cancer progression by modulating AKT signals. Author: Li N1, Kong J2, Lin Z1,3, Yang Y1, Jin T1, Xu M1, Sun J1, Chen L4,5. Journal: Br J Cancer. 2019 Apr;120(7):703-713. doi: 10.1038/s41416-019-0383-z. Epub 2019 Feb 26.    PubMed      DOI
7.	SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment. Author: Abdel-Fatah TMA1,2, Broom RJ3, Lu J4, Moseley PM1, Huang B5, Li L6, Liu S7, Chen L8, Ma RZ9, Cao W10, Wang X10, Li Y11, Perry JK12, Aleskandarany M13, Nolan CC13, Rakha EA14, Lobie PE15, Chan SYT1, Ellis IO13, Hwang LA16, Lane DP16, Green AR17, Liu DX18,19. Journal: Br J Cancer. 2019 Apr;120(7):728-745. doi: 10.1038/s41416-019-0405-x. Epub 2019 Feb 28.    PubMed      DOI
8.	Correction: Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy. Author: Liu C1, He H1,2, Li X1,3, Su MA4, Cao Y5,6. Journal: Br J Cancer. 2019 Apr;120(7):772. doi: 10.1038/s41416-019-0418-5.    PubMed      DOI
9.	Low tumour PPM1H indicates poor prognosis in colorectal cancer via activation of cancer-associated fibroblasts. Author: Xu X1,2, Zhu L3, Yang Y4, Pan Y1, Feng Z1, Li Y1, Chang W5, Sui J6, Cao F7. Journal: Br J Cancer. 2019 May;120(10):987-995. doi: 10.1038/s41416-019-0450-5. Epub 2019 Apr 16.    PubMed      DOI
10.	A novel NPM1-RARG-NPM1 chimeric fusion in acute myeloid leukaemia resembling acute promyelocytic leukaemia but resistant to all-trans retinoic acid and arsenic trioxide. Author: Chen X1, Wang F1, Zhang Y1, Teng W1, Cao P1, Ma X1, Liu M1, Tian Y2, Wang T1, Nie D1, Zhang J1, Liu H3,4,5, Wang W6. Journal: Br J Cancer. 2019 Apr 18. doi: 10.1038/s41416-019-0456-z. [Epub ahead of print]    PubMed      DOI

同类著名期刊名称 h-index CiteScore CA-A CANCER JOURNAL FOR CLINICIANS 144 160.19 Nature Reviews Clinical Oncology 127 8.04 NATURE REVIEWS CANCER 396 23.23 LANCET ONCOLOGY 274 10.07 JOURNAL OF CLINICAL ONCOLOGY 494 11.08 CANCER CELL 295 15.04 ANNALS OF ONCOLOGY 210 8.44 SEMINARS IN CANCER BIOLOGY 134 8.86 CLINICAL CANCER RESEARCH 292 8.32 CANCER RESEARCH 411 6.94

中科院JCR同大类学科的热搜期刊 浏览次数 MEDICINE 285484 CANCER RESEARCH 163610 International Journal of Nanomedicine 162000 Molecular Medicine Reports 161832 CANCER LETTERS 157100 JOURNAL OF ETHNOPHARMACOLOGY 138933 BIOMEDICINE & PHARMACOTHERAPY 136887 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 133537 Theranostics 132814 International Journal of Environmental Research and Public Health 131196